Drug intelligence / Profile preview

spp1148

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

SPP1148 is an investigational small molecule drug developed as a direct renin inhibitor for the treatment of hypertension and related end-organ diseases. It was identified as the most promising compound from Speedel's SPP1100 series of renin inhibitors. The drug acts by inhibiting renin, an enzyme involved in the regulation of blood pressure via the renin-angiotensin system. SPP1148 entered Phase I clinical trials to assess its safety and tolerability in healthy volunteers, with initial results expected in late 2007[1][2].

Targets

REN (Renin)

Beyond the preview

Go deeper on spp1148.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spp1148.

Explore the full profile